You are here

Two-Year Data Confirm Efficacy of Plegridy (Peginterferon Beta-1a) in MS Patients

Subjects demonstrate improvement in clinical and MRI outcomes

Results from the second year of the phase III ADVANCE trial have shown that the positive treatment effects of Plegridy (peginterferon beta-1a, Biogen idec) were maintained in patients with relapsing multiple sclerosis beyond the first year of the study.

The new findings were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS–ECTRIMS) in Boston.

Post hoc analyses confirmed that the positive effects of Plegridy in reducing disease activity and disability progression were maintained in year 2 of the study. A significantly higher proportion of patients treated with Plegridy during both years of the trial experienced no evidence of disease activity (defined as the absence of clinical and magnetic resonance imaging [MRI] disease activity over 2 years of treatment) compared with those who switched to Plegridy from placebo. Moreover, those treated with Plegridy during both years of the study showed significant reductions in the risk of 24-week confirmed disability progression compared with patients treated with placebo during the first year.

New data from the second year of the ADVANCE trial also showed that patients treated with Plegridy throughout the study experienced statistically significant improvements in clinical and MRI outcomes — including the annualized relapse rate, the risk of relapse, the risk of 24-week confirmed disability progression, and the number of brain lesions — compared with those who switched to Plegridy after taking placebo for the first year. These new data also showed that the safety profile of Plegridy was consistent between years 1 and 2 of the study.

Plegridy is a subcutaneous injectable therapy indicated for relapsing forms of MS. The product consists of interferon beta-1a that has been pegylated to extend its half-life, which allows a less-frequent dosing schedule. Plegridy is a member of the interferon class of treatments for MS.

Source: Biogen Idec; September 11, 2014.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs